Can Prolia (denosumab) cause tooth loss?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Prolia Does Not Directly Cause Tooth Loss, But It Is Associated With Osteonecrosis of the Jaw (ONJ), Which Can Lead to Tooth Loss as a Secondary Complication

Prolia (denosumab) does not cause routine tooth loss in the way you might lose a tooth from decay or gum disease, but it carries a small risk of osteonecrosis of the jaw (ONJ)—a serious condition where jaw bone dies and becomes exposed—which can ultimately result in tooth loss if it occurs. The absolute risk is low in osteoporosis patients (approximately 1 in 10,000 to 1 in 100,000, or 0.001% to 0.01%), but increases with longer treatment duration and invasive dental procedures 1.

Understanding the Risk: ONJ vs. Direct Tooth Loss

What Actually Happens

  • ONJ is the primary concern: This is a non-healing wound in the oral mucosa with exposed bone lasting more than 8 weeks 1
  • Tooth loss occurs secondarily: When ONJ develops, teeth in the affected area may need extraction or may be lost due to the dying bone tissue
  • The risk is dose-dependent: Higher doses used in cancer treatment carry greater risk than osteoporosis doses 1

Quantifying Your Risk

For osteoporosis patients on standard Prolia dosing:

  • Baseline risk: 0.001% to 0.01% (1-10 per 100,000 patients) 1
  • With invasive dental procedures: Risk increases to approximately 0.68% if you undergo tooth extraction or dental implants 2
  • Without dental procedures: Risk remains at 0.05% 2
  • Long-term therapy (>4 years): Risk may increase to 0.21% 1

Critical Risk Factors That Increase ONJ Risk

You are at higher risk if you have:

  • Active dental infections: Periodontitis, periapical infections, or abscesses significantly increase risk 3, 4
  • Planned invasive dental work: Tooth extractions, dental implants, or jaw surgery 1, 5
  • Concurrent medications: Corticosteroids or chemotherapy 1, 3
  • Poor oral hygiene: Inadequate dental care 5
  • Cancer diagnosis: Especially with high-dose denosumab (120 mg monthly vs. 60 mg every 6 months for osteoporosis) 6

Essential Prevention Strategy

Before Starting Prolia

Complete all necessary dental work before your first Prolia injection 5. This includes:

  • Comprehensive dental examination
  • Treatment of any active infections
  • Completion of planned extractions or implants
  • Allowing complete healing before starting medication 1

During Prolia Treatment

  • Maintain excellent oral hygiene: Daily brushing, flossing, and regular dental cleanings 5
  • Routine dental care is safe: Regular cleanings and fillings can continue 1
  • Avoid invasive procedures when possible: Extractions and implants carry the highest risk 5
  • If extraction is unavoidable:
    • Use prophylactic antibiotics 5
    • Employ minimally invasive techniques 4
    • Ensure primary wound closure 4
    • Consider timing around dosing schedule (see below) 4, 7

The "Drug Holiday" Controversy

Important caveat: Unlike bisphosphonates, stopping Prolia is potentially dangerous and generally not recommended 5, 1, 5.

Why Prolia is Different

  • No bone storage: Denosumab doesn't accumulate in bone like bisphosphonates 5
  • Rapid rebound effect: Stopping causes bone density to drop 6.6% in the spine and 5.3% in the hip within 12 months 1
  • Increased fracture risk: Multiple vertebral fractures can occur after discontinuation 5, 1, 5

If Dental Surgery is Necessary

Rather than stopping Prolia entirely, consider:

  • Timing procedures strategically: Schedule dental work 4-5 months after your last injection (when drug effect is waning) but before the next dose 4, 7
  • Never skip doses without transition therapy: If Prolia must be stopped, you need bisphosphonate therapy to prevent rebound fractures 1

Recent Evidence on Tooth Resorption

Emerging case reports suggest a possible association between Prolia and multiple external cervical root resorption (MECRR)—a rare, aggressive form of tooth damage affecting the tooth root at the gum line 8. This was observed approximately 5 years after starting therapy and paradoxically worsened after stopping the medication 8. While this doesn't establish causation, it represents another potential mechanism of tooth-related complications beyond ONJ.

Bottom Line for Clinical Decision-Making

The risk of tooth loss from Prolia is real but small, and is almost entirely preventable with proper dental care. The benefits of fracture prevention in osteoporosis typically far outweigh the ONJ risk for most patients. However:

  • Get dental clearance before starting 5
  • Maintain meticulous oral hygiene 5
  • Treat dental infections immediately 3, 4
  • Coordinate with both your dentist and prescribing physician for any invasive procedures 4, 7
  • Never stop Prolia abruptly without a transition plan to bisphosphonates 5, 1, 5

If ONJ does develop, it can be managed with antibiotics, antimicrobial rinses, and in severe cases, surgical debridement, with most cases resolving with treatment 1, 2.

References

Research

Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2021

Research

[Expert consensus on perioperative management of tooth extraction in patients receiving denosumab therapy].

Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology, 2026

Research

Two cases of tooth resorption in patients receiving denosumab therapy.

Journal of the American Dental Association (1939), 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.